Targeting the IL-33/ST2 Pathway in Colorectal Cancer Immunotherapy
结直肠癌免疫治疗中靶向 IL-33/ST2 通路
基本信息
- 批准号:10366086
- 负责人:
- 金额:$ 11.87万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-04-01 至 2022-09-30
- 项目状态:已结题
- 来源:
- 关键词:AffectAntibodiesAntigen PresentationAntigensAwardBindingBioinformaticsBiological AssayBiomedical EngineeringCD47 geneCD8-Positive T-LymphocytesCancer BiologyCell LineCellsChimeric ProteinsClinicalColonColorectal CancerCommunicationComplexDataDevelopmentDisciplineDiseaseEnvironmentGoalsHumanImmune checkpoint inhibitorImmune responseImmune systemImmunologyImmunosuppressionImmunotherapyIndianaInfiltrationInterleukin ActivationInterleukinsInvestigationJournalsKnockout MiceKnowledgeLeadLegal patentLightLiteratureLymphoblastic LeukemiaMalignant NeoplasmsManuscriptsMediatingMemoryMicrosatellite InstabilityMicroscopyModelingMolecularMolecular ProfilingMusNanotechnologyNatureOutcomePTPNS1 genePaperPathway interactionsPatientsPhagocytosisPhenotypePlayPostdoctoral FellowPublishingRectal CancerReportingResearchResearch Peer ReviewResearch PersonnelResistanceRoleSHPS-1 proteinSamplingScientistSignal TransductionSolidT cell responseT-LymphocyteTechnologyTherapeuticTherapeutic UsesTrainingTreatment ProtocolsTumor AntigensTumor-associated macrophagesUniversitiesWomananti-PD-1anti-PD1 therapyantigen-specific T cellsbasecancer cellcancer immunotherapycancer stem cellcancer vaccinationcareercell mediated immune responsecheckpoint therapyclinical investigationcolon cancer patientscytokinecytotoxic CD8 T cellscytotoxicitydeprivationdesignexperimental studyimmune checkpointimprovedinsightinterestleukemia/lymphomamacrophagemennanoneoplastic cellnovelreceptorresponseskillssmall molecule inhibitorstem cellstissue stresstranscriptome sequencingtranslational potentialtumortumor growthtumor immunologytumor microenvironmentvaccination strategy
项目摘要
Summary/Abstract:
I am a postdoctoral fellow at Indiana University who has developed a unique set of skills in tumor immunology
and cancer immunotherapy. Throughout my graduate and postdoctoral studies, I established a productive track-
record with seven first/co-first author manuscripts and a total of 18 top-tier peer-reviewed research and review
papers, including: Nature Nanotechnology, ACS Nano, Nature Communications, The Journal of Clinical
Investigation, Cancer Immunology Research and JCI Insight. Furthermore, I am listed as co-inventor on several
patent applications.
Development/Training: My long-term goal is to establish myself as an independent researcher with the focus
on cancer immunotherapy. Throughout the years, my research became unique in the immunotherapy field as I
am bridging multiple disciplines. This unique skill set requires in-depth knowledge in immunology and
immunotherapy as well as solid understanding in bioinformatics, nanotechnology and the biomedical engineering
field. The K99/R00 award will help in achieving my goal, as I will be guided towards becoming an independent
investigator under the guidance of extremely well-established scientists such as Dr. Xiongbin Lu (cancer biology)
and Dr. Sophie Paczesny (immunology and immunotherapy). I will also closely collaborate with Dr. Chi Zhang
(bioinformatics deconvolution) and Dr. Kenneth Dunn (CODEX® Technology and microscopy).
Research: Despite unprecedented clinical tumor regression observed with checkpoint immunotherapy in
colorectal cancer (CRC) patients harboring microsatellite instability high (MSI-H) tumors, a large proportion of
patients receive little to no improvement. Thus, additional checkpoint inhibitors (CPI) in new pathways are
needed; investigation of tumor microenvironment (TME) cell infiltrates and soluble factors will shed light on
possible targets as well as potential pitfalls to such immunotherapies. In this proposal, I will determine the role
of the interleukin-33 (IL-33) and its receptor STimulation 2 (ST2) in CRC immunotherapy. In my JCI Insight
published preliminary data, I established that ST2 expressing tumor associated macrophages (TAMs) hamper
CD8+ T-cell responses. I therefore hypothesize that ST2 expressing TAMs play an essential role in suppressing
antigen-specific T-cell mediated immune responses and that targeting these TAMs could serve as a potential
novel immune checkpoint pathway. Moreover, I will also investigate the role of ST2 on CRC tumor cells and the
contribution of activating the IL-33/ST2 pathway leading to cancer immunotherapy resistance. Finally, I will
assess the translational potential of IL-33/ST2 therapeutic blockade using the IL-33-trap fusion protein to trap
free local and systemic IL-33 or as an alternative approach a ST2 small molecule inhibitor that will block the
functional binding of IL-33 to its ST2 receptor complex, and these agents in combination with other checkpoint
immunotherapy. Support through this award will greatly increase my likelihood to obtain an R01 at an early
career stage.
摘要/文摘:
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
KEVIN VAN DER JEUGHT其他文献
KEVIN VAN DER JEUGHT的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('KEVIN VAN DER JEUGHT', 18)}}的其他基金
Targeting the IL-33/ST2 Pathway in Colorectal Cancer Immunotherapy
结直肠癌免疫治疗中靶向 IL-33/ST2 通路
- 批准号:
10732792 - 财政年份:2023
- 资助金额:
$ 11.87万 - 项目类别:
Targeting the IL-33/ST2 Pathway in Colorectal Cancer Immunotherapy
结直肠癌免疫治疗中靶向 IL-33/ST2 通路
- 批准号:
10215075 - 财政年份:2021
- 资助金额:
$ 11.87万 - 项目类别:
相似海外基金
University of Aberdeen and Vertebrate Antibodies Limited KTP 23_24 R1
阿伯丁大学和脊椎动物抗体有限公司 KTP 23_24 R1
- 批准号:
10073243 - 财政年份:2024
- 资助金额:
$ 11.87万 - 项目类别:
Knowledge Transfer Partnership
Role of Natural Antibodies and B1 cells in Fibroproliferative Lung Disease
天然抗体和 B1 细胞在纤维增生性肺病中的作用
- 批准号:
10752129 - 财政年份:2024
- 资助金额:
$ 11.87万 - 项目类别:
CAREER: Next-generation protease inhibitor discovery with chemically diversified antibodies
职业:利用化学多样化的抗体发现下一代蛋白酶抑制剂
- 批准号:
2339201 - 财政年份:2024
- 资助金额:
$ 11.87万 - 项目类别:
Continuing Grant
Isolation and characterisation of monoclonal antibodies for the treatment or prevention of antibiotic resistant Acinetobacter baumannii infections
用于治疗或预防抗生素耐药鲍曼不动杆菌感染的单克隆抗体的分离和表征
- 批准号:
MR/Y008693/1 - 财政年份:2024
- 资助金额:
$ 11.87万 - 项目类别:
Research Grant
Developing first-in-class aggregation-specific antibodies for a severe genetic neurological disease
开发针对严重遗传神经系统疾病的一流聚集特异性抗体
- 批准号:
10076445 - 财政年份:2023
- 资助金额:
$ 11.87万 - 项目类别:
Grant for R&D
Discovery of novel nodal antibodies in the central nervous system demyelinating diseases and elucidation of the mechanisms through an optic nerve demyelination model
发现中枢神经系统脱髓鞘疾病中的新型节点抗体并通过视神经脱髓鞘模型阐明其机制
- 批准号:
23K14783 - 财政年份:2023
- 资助金额:
$ 11.87万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Elucidation of the mechanisms controlling the physicochemical properties and functions of supercharged antibodies and development of their applications
阐明控制超电荷抗体的理化性质和功能的机制及其应用开发
- 批准号:
23KJ0394 - 财政年份:2023
- 资助金额:
$ 11.87万 - 项目类别:
Grant-in-Aid for JSPS Fellows
Role of antibodies in hepatitis E virus infection
抗体在戊型肝炎病毒感染中的作用
- 批准号:
10639161 - 财政年份:2023
- 资助金额:
$ 11.87万 - 项目类别:
Defining the protective or pathologic role of antibodies in Post-Ebola Syndrome
定义抗体在埃博拉后综合症中的保护或病理作用
- 批准号:
10752441 - 财政年份:2023
- 资助金额:
$ 11.87万 - 项目类别:
Human CMV monoclonal antibodies as therapeutics to inhibit virus infection and dissemination
人 CMV 单克隆抗体作为抑制病毒感染和传播的治疗药物
- 批准号:
10867639 - 财政年份:2023
- 资助金额:
$ 11.87万 - 项目类别: